185448-75-3

Upstream product

• 2916-68-9 2-(Trimethylsilyl)ethanol 
• 50721-37-4 S-5-benzyloxycarbonylamino-2-hydroxypentanoic acid 
• 70-26-8 L-ornithine 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 185448-62-8 (S)-5-Benzyloxycarbonylamino-2-{(R)-2-(tert-butoxycarbonyl-methyl-amino)-3-[1-(tert-butyl-dimethyl-silanyl)-1H-indol-3-yl]-propionyloxy}-pentanoic acid 2-trimethylsilanyl-ethyl ester 
• 185448-59-3 5-[(benzyloxycarbonyl)amino]-(2S)-2-{[N-((2S)-2-{[N-((2S)-2-{[N-(tert-butoxycarbonyl)-N-methyl-O-benzyl-L-tyrosyl]oxy}-3-methylbutanoyl)N-methyl-L-valyl]oxy}-3-methylbutanoyl)-N-methyl-D-tryptophanyl]oxy}pentanoic acid 2-(trimethylsilyl)ethyl ester 
• 185448-58-2 C₆₃H₈₁N₅O₁₅ 
• 185448-57-1 (S)-5-Benzyloxycarbonylamino-2-[(R)-2-({(S)-2-[(S)-2-({(S)-2-[(S)-3-(4-benzyloxy-phenyl)-2-methylamino-propionyloxy]-3-methyl-butyryl}-methyl-amino)-3-methyl-butyryloxy]-3-methyl-butyryl}-methyl-amino)-3-(1H-indol-3-yl)-propionyloxy]-pentanoic acid 
• 185448-54-8 {3-[(2S,5S,8S,11S,14S,17R)-5-(4-Benzyloxy-benzyl)-17-(1H-indol-3-ylmethyl)-8,11,14-triisopropyl-4,10,16-trimethyl-3,6,9,12,15,18-hexaoxo-1,7,13-trioxa-4,10,16-triaza-cyclooctadec-2-yl]-propyl}-carbamic acid benzyl ester 
• 185448-55-9 (3S,6S,9R,12S,15S,18S)-6-(3-Amino-propyl)-3-(4-hydroxy-benzyl)-9-(1H-indol-3-ylmethyl)-12,15,18-triisopropyl-4,10,16-trimethyl-1,7,13-trioxa-4,10,16-triaza-cyclooctadecane-2,5,8,11,14,17-hexaone 
• 185448-64-0 (S)-5-Benzyloxycarbonylamino-2-[(R)-2-(tert-butoxycarbonyl-methyl-amino)-3-(1H-indol-3-yl)-propionyloxy]-pentanoic acid 2-trimethylsilanyl-ethyl ester 
• 185448-66-2 (S)-5-Benzyloxycarbonylamino-2-[(R)-3-(1H-indol-3-yl)-2-methylamino-propionyloxy]-pentanoic acid 2-trimethylsilanyl-ethyl ester 

Relevant academic research and scientific papers

Design, synthesis, and evaluation of a depsipeptide mimic of tendamistat

The cyclic hexadepsipeptide framework of enniatin B was identified as a template matching the β-turn tripeptide of tendamistat. The modified analog 1 was synthesized as a tendamistat mimic and compared to the acyclic derivative 2 and the tripeptide Ac-Try-Arg-Tyr-OMe. These compounds were assembled from the dimeric esters 3-5. As an inhibitor of α-amylase, 1 is twice as potent as 2 and comparable to the tripeptide. NMR studies of 1 reveal four conformers in equilibrium in a 50:25:15:10 ratio; the ring conformation of the major component is similar to that of the enniatin B template, with the cis geometry of the α-hydroxyisovaleryl-N-methylvaline amide linkage; the other conformers differ in the position or presence of the cis amide linkage.